Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism

31Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Hyperhomocysteinemia (HHC) is an independent risk factor for cardiovascular disease, and even mildly to moderately elevated homocysteine levels have been associated with a heightened risk for a first and recurrent venous thromboembolism (VTE). Within the frame of a large prospective cohort study (Austrian Study on Recurrent Venous Thromboembolism), we assessed the impact of HHC on the risk of recurrence among 602 patients with a first unprovoked VTE. HHC was an independent risk factor of recurrence conferring a relative risk of 1.5 (95th% CI 1.0-2.4). HHC is caused either by genetic defects and/or by a deficiency of the vitamins (B12, B6 and folic acid) involved in the homocysteine metabolism. Low vitamin B6 levels are associated with an increased risk of a first venous thrombosis. We currently investigate whether or not low plasma levels of PLP are associated with a heightened risk for recurrent VTE. Copyright © 2004 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Eichinger, S. (2003). Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism. In Pathophysiology of Haemostasis and Thrombosis (Vol. 33, pp. 342–344). https://doi.org/10.1159/000083825

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free